While a number of virus-based delivery schemes have been developed for myocardial gene transfer, no technique has proven capable of modifying a majority of cardiac myocytes rapidly and homogeneously in the in vivo rat model, and most schemes result in significant infection of the liver and other organs. However, adenoviral delivery to the excised heart during retrograde perfusion can produce 67-92% efficient gene transfer. In this study, we adapt this isolation/perfusion scheme to the heart in vivo. We isolated the heart in vivo by simultaneously clamping all vessels to/from the heart. The heart was then continuously retrograde perfused through a catheter positioned in the aortic root. A second catheter in the right ventricle provided a path for efflux. After perfusing the heart for 7.5 min with calcium-free Tyrode solution followed by 90 s no-flow viral exposure (AdV.cmv.LacZ; 10 12 viral particles/ml), gene transfer efficiency was 60% compared to 5% by a conventional cross-clamp technique. Infection of peripheral organs was dramatically reduced. Given the prevalence of the rat in so many models of heart disease, this enhancement of infection represents an advancement in viral-based delivery of exogenous genes to heart for the study of gene therapy in vivo. Gene Therapy (2005) 12, 958-964.
Introduction
The use of virus-based vectors for gene transfer in heart has emerged as a powerful approach to overexpress and access the function of key enzymes and proteins in healthy and diseased heart. Several transfer schemes have been developed for delivery of viral vectors to heart in vivo. These include direct injection of the virus into the cardiac wall, 1 intracoronary artery delivery, 2 aortic crossclamp approaches, 3, 4 cardiac bypass, 5 and ultrasound targeted microbubble delivery. 6 The goal of each scheme is to maximize the number of infected cardiac cells (ie, efficiency), and minimize infection of peripheral tissue without jeopardizing the health of the animal.
Successful, high-efficiency infection of the heart in vivo has been reported for hamster and mouse. 3, 7, 8 Ikeda et al 3 reported 77% infection of whole heart in hamster by injecting virus into the aortic root after occluding the ascending aorta and pulmonary artery. Champion et al 7 achieved 60% infection of whole heart in mouse by clamping the descending aortic artery and maintaining an upper body perfusion circuit. 7 Both methods relied on cooling the body to allow cross-clamp times ranging from 5 to 10 min. Despite these advances, highly efficient, homogeneous gene transfer in rat has not been reported. Given the prevalence of the rat in so many models of heart disease, this obstacle remains compelling. Adenoviral (AdV) transfer of exogenous gene has also been used to infect the isolated intact heart in order to identify and optimize the key conditions required to achieve the highest level of gene transfer. [9] [10] [11] In the isolated model, the heart is excised, connected to a Langendorff apparatus, and perfused with a solution containing the adenovirus. The tissue is then digested, the cells isolated, cultured, and the infection is accessed at 24-48 h. By this approach, Donahue et al 9, 10 characterized the level of infection for different viral concentrations, exposure times, temperatures, and perfusion flow rates. In agreement with others, they also reported the value of both pretreating the heart with a microvascular permeability agent and delivering the adenovirus in a crystalloid solution. 10 Optimizing each of these conditions, Donahue et al achieved 92% efficient gene transfer in isolated rabbit heart. Similarly, Logeart et al 11 achieved 67% efficient gene transfer in the isolated rat heart. While the isolated method does not depend on animal survival, these studies clearly demonstrate that a continuously perfused isolated heart satisfies many of the key conditions required to achieve highly efficient gene transfer in whole heart. In this study, we adapt both the Donahue et al and Logeart et al infection protocols for the excised heart to the in vivo animal model, determine if the same high level of efficiency can be achieved, and compare the result to infection by the conventional in vivo cross-clamp approach.
Results
Animal survival postinfection Figure 1 provides a summary of the three protocols studied. Protocol 1. Rat hearts were infected in vivo with AdV.cmv.LacZ by the conventional aortic/pulmonary artery 30 s cross-clamp technique. 4 All 10 rats recovered from the procedure and nine survived through the 72 h postinfection period. Protocol 2. Hearts were isolated in vivo by simultaneously cross-clamping all vessels to/from the heart for 8 min while AdV.cmv.LacZ was delivered via retrograde perfusion at a flow rate of either 10 or 30 ml/min. At 10 ml/min, nine of 10 animals regained a heartbeat and recovered from anesthesia. The rats recovered quickly and had grossly normal neurological function, activity, and eating behavior. Eight of these animals survived the 72 h postinfection period before they were euthanized for assessment of exogenous gene transfer. At 30 ml/min, none of the four animals regained a heartbeat after releasing the crossclamp. All deaths occurred while under anesthesia and data were not included in any of the analysis. Protocol 3. In the third protocol, hearts were isolated in vivo and perfused at 3-5 ml/min with calcium-free Tyrode buffer for 7.5 min before injecting the AdV.cmv.LacZ solution for a 90 s infection period. Six of the eight rats recovered from the procedure and survived the 72 h postinfection period. Importantly, the final 15 s washout with welloxygenated Tyrode solution containing normal levels of calcium (1.5 mM) was required to ensure survival. In preliminary studies without the final washout phase, no rat regained a heartbeat after releasing the cross-clamp.
Transgene expression for heart in vivo
Figures 2 and 3 show cross-sections from whole heart stained for LacZ expression (an X-Gal stain) 72 h after infection. Figure 2a shows the level of LacZ expression from a heart infected by the conventional aortic/ pulmonary artery cross-clamp technique (Protocol 1). The blue stain indicates infected regions. In agreement with previous reports for hamster and rabbit, 3, 12 infection was low (5%, see Table 1 ) and heterogeneous. The heart shown in Figure 2b was infected according to Protocol 2 (8 min isolation, continuous perfusion with low-calcium buffer containing histamine and AdV.cmv.LacZ). The infection is significant, yet heterogeneous. This infection was achieved at a perfusion flow rate of 10 ml/min, whereas at 30 ml/min the animals did not recover. We also isolated and counted the percentage of myocytes stained positive with X-Gal, and found that the level of efficiency was 23710%. Figure 3 shows the extent of LacZ expression through multiple cross-sections of a heart 72 h after infection according to Protocol 3. The heart was isolated in vivo and perfused for 7.5 min with calcium-free Tyrode solution before a single injection of the virus (90 s viral exposure). Importantly, this strategy resulted in significant infection of the whole heart (58711% efficiency). Cells isolated from a heart infected in vivo by this technique (Protocol 3) are shown in Figure 4 . Note that phosphate-buffered saline (PBS)-injected control hearts for each protocol (not pictured) showed no positive staining for LacZ expression in heart.
We noted several key methodological nuances that influenced the level of infection in the heart. First, during viral injection, no tension could be put on the heart. If the heart was stretched or compressed during injection of the virus, infection was focus to the atria and right ventricle, suggesting compromised coronary perfusion. In addi- Gene delivery to animal heart in vivo JM O'Donnell and ED Lewandowski tion, the heart did not perfuse properly if the left ventricle filled with perfusate during the isolation. If the left ventricle appeared to hyperextend during perfusion, a second catheter was inserted into the left ventricle to reduce pressure. We also noted an important limitation with the preparation of the virus. Viral amplifications taken out past five passages yielded the very high titers required; however, the expression of LacZ was reduced in the infected heart. This is consistent with the known rearrangement of the Ad5.LacZ vector at the sixth passage. 13 For this reason, we always started with first-generation virus and stopped the amplification at the fifth passage.
Organ-specific infection
We assessed the level of AdV.cmv.LacZ infection in heart, liver, lung, and skeletal muscle based on an assay quantifying b-Gal activity. The intent was to determine if the isolated perfusion approach reduces infection of peripheral tissue compared to the conventional crossclamp approach. Results are shown in Figure 5 . In liver, b-Gal activity was dramatically reduced for Protocols 2 and 3 compared to the cross-clamp approach of Protocol 1. Infection of lung and muscle was nearly undetectable for Protocols 2 and 3. Conversely, the level of b-Gal activity in the heart (ie infection) was 4-10 times greater by Protocols 2 and 3 compared to the conventional crossclamp approach (Protocol 1). The reduction in the infection of peripheral organs is consistent with having flushed all unsequestered virus from the heart prior to releasing the cross-clamp. (In spleen, b-Gal activity was measured for Protocol 3; 40.3710.6 relative light unit (RLU)/mg protein/min n 1000, n ¼ 4). As a control for the b-Gal assay, we also assessed b-Gal activity in the various organs following PBS injection into the heart. AdV.cmv.LacZ was excluded. Without the virus, no b-Gal activity was detected in the heart, lung, and skeletal muscle. Interestingly, the liver and spleen did show a small, yet positive background reading for b-Gal activity (liver 31715 and spleen 3777 RLU/mg protein/min n 1000, n ¼ 3).
Histological analysis
We assessed the degree of myocardial injury from analysis of stained histologic sections of rat hearts infected according to Protocol 3 with either Ad.cmv.LacZ (n ¼ 4) or saline injection (n ¼ 3) (slides not shown). The results were compared to slides prepared from hearts not undergoing surgical intervention. The integrity of the tissue structure was well preserved for all groups. The hearts undergoing Ad.cmv.LacZ or saline injection showed no signs of patchy or transmural myocardial inflammation or necrosis, which could be associated with viral-induced injury by 72 h post-treatment. This result was expected since other laboratories have reported that is the perfused heart with recirculated virus; Protocol 3 (gray bar) is the pretreated heart with calcium-free buffer for 7.5 min before virus delivery. Note that liver infection is significantly reduced following Protocols 2 and 3, because unsequestered virus was flushed from the heart before releasing the crossclamp (asterisk denotes significant difference from Protocol 1, Po0.05).
Figure 4
Representative photograph of myocytes isolated from heart following infection in vivo with AdV.cmv.LacZ and stained with X-Gal. Isolated cells were used to quantify the percentage of infected myocytes for each protocol. Gene delivery to animal heart in vivo JM O'Donnell and ED Lewandowski the viral-induced inflammation response is generally first observed 4 days after adenoviral infection. 3 In addition, tissue injury was minimal and totally predicted. As several other laboratories have reported, there is injury at the site that the catheter is inserted into the heart. 12, 14 This site is typically characterized by localized necrosis and inflammatory cell infiltrates. There was also a minor degree of inflammation on the outer surface of the heart. This inflammation, which was observed for both the saline and adenovirus groups, is consistent with having removed the pericardium, extracting the heart from the chest, and manipulating the tissue during the infection protocols. The injury to the outer surface of the heart and at the site of catheter insertion is consistent with the invasiveness of the procedure.
Discussion
Conventional cross-clamp approach Consistent with findings by Hajjar et al 4 and Del Monte and Hajjar, 15 we also observed infection throughout the whole heart by adenoviral delivery at the aortic root during a 30 s occlusion of the aorta and pulmonary artery (Protocol 1). Our laboratory observed a heterogeneous infection at 5% efficiency. This level of infection is consistent with other laboratories reporting a similar low level of efficiency for hamster and rabbit heart in vivo by the same technique. 3, 12 Factors implicated in limiting the infection efficiency are perfusion pressures, mixing of virus with blood, limitation of viral exposure time, and poor endothelial barrier permeability.
9,10

Methodological considerations
Adapting the Langendorff infection technique to the in vivo model solves many of the gene transfer limitations currently recognized. Isolating the heart in vivo and flushing blood from the coronary bed prior to viral delivery eliminates the inactivation, dilution, and sequestration of viral particles by blood products. The initial isolation and perfusion period prior to viral delivery enables the heart to be treated with permeability agents. This pretreatment period can last up to 10 min during which time the animal core body temperature can be cooled below 301C to avoid neurological damage. Conversely, the perfusate and heart temperature can be maintained at 371C to optimize the activity of the temperature-sensitive virus. Importantly, the isolated heart in vivo is not ischemic during the permeability treatment phase because the perfusate being delivered to the heart is well oxygenated. During the final washout phase, the permeability agent and unsequestered virus is flushed from the heart with well-oxygenated buffer containing normal levels of calcium (1.5 mM). This aids in recovery and reduces infection of peripheral tissue.
Permeability enhancement strategies
One key advantage of the technique is the ability to treat the heart with permeability agents in vivo. The value of a pretreatment strategy has been demonstrated for infection in both the excised heart and in vivo.
3,10 Perfusing the excised rabbit heart with serotonin, bradykinin, or low-calcium Krebs solution for 15 min prior to adenoviral delivery, Donahue et al 10 found that 70-80% of cells were infected compared to 20% without the treatment. Similarly, Logeart et al 11 reported 67% efficiency in the excised rat heart pretreated for 10 min with calcium-free Tyrode solution. With normal calcium levels (2 mM), they reported 5% efficiency. In the in vivo hamster model, Ikeda et al 3 occluded the aorta and pulmonary artery and injected a bolus of cardioplegic solution containing histamine 3-5 min prior to adenovirus delivery. This resulted in 77% efficiency. For both the in vivo and isolated heart studies, it was suggested that the pretreatment strategy enhances microvascular permeability by endothelial gap fenestration, allowing adenovirus to enter the extravascular space.
By adapting the Logeart et al protocol to our model (Protocol 3), we observed 58% infection of the whole heart in vivo. This compares favorably to the 67% reported by Logeart et al 11 for the infection of the excised heart. Whereas Logeart et al pretreated the excised heart with a calcium-free buffer solution for 10 min prior to a 60 s no-flow period after adenovirus delivery, we pretreated the in vivo heart for 7.5 min with a calciumfree buffer prior to a 90 s no-flow viral exposure. In support of Logeart et al's findings, our results show that efficient adenovirus-mediated gene transfer to cardiac myocytes can be achieved by a single-pass intracoronary vector delivery, given the vascular permeability is first increased and coronary flow is briefly interrupted.
Controlled flow rates
The Langendorff perfusion approach also offers the benefit of controlled flow rates during infection. Donahue et al 9 correlated the dependence between gene transfer and flow rate in the excised rabbit heart model. The percent of infected cells increased from 10 to 40% as flow rate was increased from 10 to 30 ml/min during viral delivery to the heart. However, above 30 ml/min, perfusion pressure and efficiency did not increase significantly. They speculated that a more likely cause of the flow dependence is the presence of precapillary sphincters that open in response to some threshold pressure.
While flow rate is easily controlled in vivo by the Langendorff approach, we did find an important limitation under the conditions of Protocol 2. A total of 80% of the animals recovered if perfused at 10 ml/min for 8 min, whereas no animal recovered for flow rates at 30 ml/min. This result is consistent with injury data Emani et al 16 presented for intracoronary perfusion flow rates ranging from 1 to 30 ml/min. At a flow rate of 30 ml/min, myocardial injury scored 3.0 on a scale of 1-5, while at 10 ml/min the extent of injury scored 0.45. Consistent with these data, we find that the optimal flow rate reported by Donahue et al for the excised heart (30 ml/min) cannot be sustained in vivo for 8-10 min. This would account, in part, for the lower efficiency we report for our protocol (2) compared to their ex vivo protocols. However, it remains to be determined if animals could recover from shorter periods at flow rates of 30 ml/min.
Peripheral tissue infection
We were encouraged by the relative specificity of infection achieved by this model (Figure 5 ), illustrating one clear advantage of this technique for cardiac gene delivery. Most delivery approaches that are similarly Gene delivery to animal heart in vivo JM O'Donnell and ED Lewandowski based on coronary perfusion and that do not use a cardiac specific promoter report significant infection of peripheral tissue. 3, 4, 7 Gene transfer is particularly evident in the liver and spleen in these studies. Using our technique, we find a dramatic reduction in the infection of liver, lung, and skeletal muscle compared to the conventional cross-clamp technique. The reduction can be accounted for by the complete isolation of heart during viral delivery followed by the final washout process.
Postinfection washout
The intent of the final washout phase was to void the heart of unsequestered virus prior to releasing the occlusion. While this reduced the infection of peripheral tissue, it was not known whether washout would also reduce the efficiency of infection of the heart. From b-gal activity measurements taken from the left ventricle of hearts with or without washout following Protocol 2, we found no degradation in infection. What was more impressive with washout was heart recovery. Without washout, those hearts subjected to the 9 min of calciumfree cardioplegia (Protocol 3) did not recovery, whereas recovery was 80% for those animals subjected to the final 15 s washout phase with Krebs (1.5 mM calcium) buffer solution prior to releasing the cross-clamp.
Implications for gene therapy
One disadvantage of the technique is the invasiveness of the procedure. Opening the chest and inserting a catheter through the left ventricle, past the aortic valve, and into the aortic root for viral delivery, has its inherent sites of injury, including the potential for valvular damage. The technique would not lend itself well to gene transfer in the heart of humans. Our intent, however, was to enhance the method for gene delivery in the heart of rats, not humans. Future work could utilize this method to determine the functional and biochemical consequence of specific gene expression in healthy and diseased animal heart, an important precursor to human studies.
Achieving 100% efficient gene transfer to cells in vivo may have an important limitation. In an earlier study, isolated neonatal rat myocytes were infected with various exogenous genes at a multiplicity of infection ranging from 1 to 40 PFU/cell. 17 Above 4-5 PFU/cell, apoptotic pathways were triggered and myocyte viability was compromised. Translating this in vitro work to the in vivo scenario, as efficiency of infection for a heart in vivo approaches 100%, it can be expected that a number of cells would be infected by more than one virus. Accordingly, it remains to be determined if this would compromise cell viability in vivo and limit the physiological benefit of the gene therapy.
Conclusion
In summary, an advancement to the original cross-clamp technique has been presented that represents a novel approach to the goal of achieving highly efficient vectormediated gene transfer throughout the myocardium in vivo. With the goal of enhancing gene transfer in rat heart, our strategy optimizes several infection conditions in vivo based on the factors identified in excised heart studies. By this approach we can (1) control transmyocardial flow rate, (2) assess the benefit of several pretreatment strategies used to enhance permeability, (3) control viral concentrations, exposure times, cardioplegic composition, and body versus heart temperatures, and (4) minimize infection of peripheral tissue by completely isolating the heart in vivo during the infection period.
Methods Adenoviral viral vectors
AdV.cmv.LacZ containing the Escherichia coli lac Z gene driven by a cytomegalovirus promoter (cmv) was purchased from QBIOgene (Carlsbad, CA, USA). Firstgeneration viruses were amplified through five passages. Viral stocks were amplified in HEK293 cells (70 p150 plates, infected at 20 PFU/cell, harvested, centrifuged, and resuspended in 10 ml PBS). After four freeze/thaw cycles, the viral solution was purified in a single cesium column, and dialyzed in Tris solution (pH 7.4). The titer was determined by absorption measurements at OD 260 (typically 1-3 Â 10 12 viral particles/ml). Purity and titer were periodically confirmed by plaque purification. The typical viral particles:PFU ratio was 50. The final viral preparation was used for direct injection into the aortic root via Protocols 1 and 3. The virus was diluted with PBS 1:3 for Protocol 2.
Adenoviral delivery in vivo
Conventional cross-clamp method. This method has been described extensively in previous reports. 4, 15 In brief, the chest was entered by a median sternotomy and a 22-gauge catheter containing 200 ml of adenoviral solution was advanced from the apex of the left ventricle to the aortic root. The aorta and pulmonary arteries were clamped distal to the site of the catheter and the solution was injected. The clamp was maintained for 30 s. Only those hearts demonstrating the hallmark 'blanching', or whitening, during viral injection were maintained postoperatively for assessment of infection.
In vivo Langendorff gene transfer. The in vivo Langendorff technique described here advances the aortic/ pulmonary artery cross-clamp technique as described by Hajjar et al. 4 Our advancement enabled a completely isolated heart to be continuously retrograde perfused, in vivo. Figure 6 illustrates a heart instrumented for in vivo retrograde perfusion.
Adult Sprague-Dawley rats (350 g) were anesthetized, intubated, and placed on an ice pad to cool the core body temperature to 301C. While the temperature lowered, the chest was opened from the right side at the second or third intercostal space. The pericardium was opened and 4-0 suture was placed at the apex of the heart (see Figure  6 ). The suture was used to control handling of the heart. A 20-gauge catheter was inserted through the apex into the left ventricle. The tip of the catheter was advanced to the aortic root. Placement of the tip was verified by observing the tip through the wall of the ascending aorta. The other end of this catheter was connected to tubing for delivery of perfusate solution and adenovirus via a peristaltic pump. The catheter was tied to the 4-0 suture that was placed at the apex of the heart. This kept the catheter from sliding out of position during the perfusion protocol.
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The heart was externalized from the rib cage and all vessels leading to and from the heart (superior/inferior vena cava, pulmonary artery/vein, and ascending aorta) were occluded simultaneously with a single cross-clamp. The clamp was distal to the catheter positioned in the aortic root. A 24-gauge catheter was inserted into the right ventricle (see Figure 6 ). This catheter provided a path for perfusate efflux from the heart. Next, the heart was retrograde perfused via the catheter in the aortic root with buffer at a flow rate of 3-30 ml/min. Depending on the protocol, the efflux was either discarded or collected, oxygenated, filtered, and recirculated to the heart. Following a permeability treatment phase and viral injection, the heart received a washout perfusion phase. For 15 s the heart was perfused from a reservoir of well-oxygenated Krebs buffer containing normal levels of calcium (1.5 mM). This washout period aided in contractile recovery and purged any unsequestered virus from the heart following infection.
The perfusion was stopped after washout and the catheters and clamp were removed. The chest was closed, air was evacuated, and the body was warmed to 371C. Once the animal could breath independently, the rat was moved to an oxygen chamber until it recovered from the anesthesia (1 h). Figure 1 summarizes the three protocols studied. Protocol 1. The aorta and pulmonary artery were cross-clamped in vivo and adenovirus (AdV.cmv.LacZ; 1 Â 10 12 particles/ml, 0.2 ml, see Table 1 ) was delivered into the aortic root by the method reported by Hajjar et al 4 and DelMonte and Hajjar 15 as described above.
Protocols for in vivo gene transfer
Protocol 2. By this protocol, the heart was initially isolated and perfused with histamine and low-calcium cardioplegic solution to improve permeability, and infection was assessed for two different perfusion flow rates. First, the heart was isolated in vivo and blood was flushed out with modified Krebs-Henseleit buffer at 371C containing (mmol/l) 116 NaCl, viral particles/ml). The volume of viral solution was 1.5 ml and included histamine. As the perfusate dripped from the heart, it was collected, filtered, and recirculated (multipass) for 6 min at a flow rate of either 10 (n ¼ 10) or 30 (n ¼ 4) ml/min. The perfusate was then switched to well-oxygenated Krebs buffer containing normal levels of calcium (1.5 mM), without histamine, for a 15 s washout phase (3-5 ml/min) before releasing the crossclamp.
Protocol 3. Hearts were isolated in vivo and perfused with well-oxygenated calcium-free Tyrode solution for 7.5 min at 3-5 ml/min prior to adenoviral delivery (n ¼ 8, AdV.cmv.LacZ). The Tyrode solution contained (mmol/l) 159 NaCl, 8 KCl, 4.47 MgCl 2 , 0.79 NaH 2 PO 4 , 25 NaHCO 3 , and 10 HEPES. The efflux of the buffer from the heart was discarded. Following this pretreatment phase, the peristaltic pump was stopped and 0.4 ml of viral solution was injected quickly (2 s) into the heart through the same catheter (AdV.cmv.LacZ; 1 Â 10 12 viral particles/ ml). After 90 s (no-flow), unsequestered virus was flushed from the heart for 15 s (3-5 ml/min) with welloxygenated Krebs solution containing normal levels of calcium (1.5 mM).
X-Gal staining and efficiency
LacZ expression was assessed based on X-Gal staining of the whole heart. At 72 h after infection, rats were given heparin, anesthetized, hearts were isolated, and the aorta was canulated. Each heart was flushed (20 ml) via the canuli with the following rinsing/fixing solutions, and bathed in the same solution for the indicated time: (1) PBS rinse; (2) 0.5% glutaraldehyde, 30 min, followed by PBS rinse; (3) 30% sucrose, 30 min, followed by PBS rinse; (4) sodium deoxycholate (0.01%) and IPEGAL, Figure 6 Rat heart is shown instrumented for in vivo retrograde perfusion. A catheter is inserted into the left ventricle and the tip of the catheter is advanced to the aortic root. The heart is externalized from an opening in the chest and all vessels to/from the heart are cross-clamped simultaneously. Cardioplegic solution containing a permeability agent and/or the adenoviral vector is continuously delivered through the catheter in the left ventricle. Coronary efflux passes from the catheter position in the right ventricle.
Gene delivery to animal heart in vivo JM O'Donnell and ED Lewandowski 15 min, with no rinse; and (5) X-Gal (first dissolved in dimethylformamide, then PBS). Immediately after the final flush with X-Gal buffer, the heart was sliced into 3 mm sections and bathed in the X-Gal solution overnight. Results for X-Gal staining are shown in Figures 2  and 3 .
To quantify the percentage of myocytes expressing LacZ, cells were isolated from those cross-sections of hearts stained for X-Gal. The stained sections were minced into 1 mm pieces and digested in collagenase (4 mg/ml dH 2 O, Worthington Biochemical Inc., Lakewood, NJ, USA) solution for 6 h. The solution was constantly stirred during this period (stir bar) and triturated every 30 min. Undigested pieces were removed, and the supernatant was centrifuged to concentrate the cells. As illustrated in Figure 4 , the cells were resuspended in H 2 O, plated, and positive/negative cells stained via X-Gal were randomly viewed and counted.
Organ-specific b-galactosidase activity LacZ expression was semiquantitatively assessed in left ventricle, liver, lung, and hind limb skeletal muscle by a colorimetric assay for b-Gal activity (SIGMA, kit #GAL-A). At 72 h after infection, the rats were killed and tissue samples were excised and homogenized in lyses buffer. The resulting homogenate was centrifuged at 14 000 r.p.m. for 8 min, and an aliquot of the supernatant was added to b-Gal reaction buffer. A blank was prepared for each sample that included an equal aliquot of tissue homogenate. b-Gal reaction buffer was excluded from the sample blanks. Reactions were stopped after color development, and light emission was measured by an illuminometer in RLU/min. Activity was normalized for protein content. Protein content from the homogenate of each sample was determined by modification of the Lowry method (BCA protein assay reagent, Pierce Biotechnology Inc., Rockford, IL, USA).
Histological analysis
Hematoxylin/eosin and Masson's trichrome stainings were performed on microscopic cross-sections of heart to assess and differentiate viral-induced inflammation and surgically induced injury. The 10 mm slices were prepared 72 h postinfection and examined for hypertrophy, hyperplasia, inflammatory cell infiltrates, septal defects, necrosis, mineralization, fibrosis, cytoplasmic vacuolization, and altered cell orientation. The slides were examined by a single investigator blinded to the treatment status of each animal.
Statistics
Data are reported as mean7s.d. Data set comparisons were performed with Student's unpaired, two-tailed t-test. Differences in mean values were considered statistically significant at a probability level of o5% (Po0.05).
